SBIR/STTR Research Award

Tea Tree Oil for Treating Ocular Demodex Infestation

Award identifier e9bd85cb73962015f83961f273d7ce4f2fcfa4a608ecdde34345ff9ec37d5d26Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$112,409

Program and phase

SBIR · Phase I

Award year

2009

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
BIOTISSUE HOLDINGS INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
C4GJA1DTK7L1
Solicitation number
PHS2009-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Demodex (folliculorum and brevis) mites are microscopic ectoparasites that commonly infest the pilosebaceous unit of the skin. Uncontrolled overgrowth of these mites has been implicated in causing rosacea in the face, blepharitis in the eyelid, and other inflammation-associated conjunctival and corneal abnormalities. We have conducted a number of studies to substantiate the potential pathogenicity of demodex mites in causing eye irritation and inflammation in patients. We have improved the accuracy of diagnosing demodex infestation based on sampling lashes from the patient, and established that lashes harboring cylindrical dandruff are a reliable sign indicative of demodex infestation. Furthermore, we have developed an in vitro assay to screen agents that can potentially kill adult demodex mites. Using this assay, we have discovered that the Baby Shampoo does not, but tea tree oil (TTO), an essential oil distilled from Melaleuca alternifolia does, kill mites. We further showed that weekly office lid scrub with 50% TTO solution followed by daily home lid hygiene with tea tree shampoo can eradicate ocular Demodex in a majority of the suffering patients. However, this regimen achieves eradication of demodex infestation in the majority, but not all, of the patients, generates eye irritation in some patients, and is still not simple enough for patients to self administer it at home. In the SBIR Phase I application, we would like to identify the most active ingredient in TTO that may kill adult demodex mites in vitro, to examine the safety/toxicity of ophthalmic formulations containing this active ingredient in an in vitro cytotoxicity test and rabbit eyes, and to determine the stability of such formulations under different storage conditions and durations. Accomplishment of these three aims will allow us to collect sufficient data for obtaining an IND approval from the FDA so that we may conduct, in Phase II, clinical studies, eventually leading to the development of the first FDA-approved prescription ophthalmic formulation containing the most active ingredient in TTO to eradicate ocular demodex infestation in this most common eye disease. PUBLIC HEALTH RELEVANCE: This research is aimed to developing the first FDA-approved prescription drug containing the most active ingredient in tea tree oil to eradicate Demodicosis (the microscopic infestation of the hair follicle and the oil gland by Demodex mites) commonly occurring in the skin and the eyelid. Demodicosis is one of the leading causes of blepharitis, a common eye disease, for which eradication has not been achieved by any over-the-counter lid scrub regimen. Because Demodex infestation is prevalent in the older population, an effective treatment as such for eradicating Demodicosis for the eye will address an important public health concern when the aging population is increased, and help to develop a similar treatment for the skin in the future.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

14 SBIR/STTR records share this UEI (2003–2016). Reported award amounts total $7,392,317. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.